LGALS3 and Alzheimer disease: We hypothesized that a Gal-3-targeted nanoplatform, engineered to co-deliver NO and RES with spatial specificity and pathological cue-responsive release, could modulate AD-relevant pathological processes by selectively targeting key cellular drivers across disease stages (Scheme 1).